Table 3 Adequate clinical and Parasitological response (ACPR) in the intention-to-treat population
Pyronaridine–artesunate (n = 101) | Artemether–lumefantrine (n = 96) | Difference (95% CI) | |
|---|---|---|---|
Day 28 | |||
PCR-corrected ACPR, n/Na | 93/101 | 81/96 | |
% (95% CI) | 92.1 (85.1 to 95.9) | 84.4 (75.8 to 90.3) | 7.7 (− 1.4 to 17.1) |
Total no. of failures | 8 (7.9) | 15 (15.6) | |
No. with missing data | 6 (5.9) | 11 (11.5) | |
No. with early treatment failure | 0 | 0 | |
No. with late clinical failure | 0 | 0 | |
No. with late parasitological failure | 1 (1.0) | 3b (3.1) | |
No. with reinfection < day 28 | 1 (1.0) | 1 (1.0) | |
Uncorrected ACPR, n/N | 87/101 | 75/96 | |
% (95% CI) | 86.1 (78.1 to 91.6) | 78.1 (68.9 to 85.2) | 8.0 (− 2.7 to 18.8) |
Total no. of failures | 14 (13.9) | 21 (21.9) | |
No. with missing data | 6 (5.9) | 11 (11.5) | |
No. with early treatment failure | 0 | 0 | |
No. with late clinical failure | 1 (1.0) | 1 (1.0) | |
No. with late parasitological failure | 7 (6.9) | 9 (9.4) | |
Day 42 | |||
PCR-corrected ACPR, n/Na | 73/101 | 61/96 | |
% (95% CI) | 72.3 (62.9 to 80.1) | 63.5 (53.6 to 72.5) | 8.7 (− 4.3 to 21.4) |
Total no. of failures | 28 (27.7) | 35 (36.5) | |
No. with missing data | 15 (14.9) | 19 (19.8) | |
No. with early treatment failure | 0 | 0 | |
No. with late clinical failure | 1 (1.0) | 0 | |
No. with late parasitological failure | 3b (3.0) | 6c (6.3) | |
No. with reinfection < day 42 | 9 (8.9) | 10 (10.4) | |
Uncorrected ACPR, n/N | 67/101 | 56/96 | |
% (95% CI) | 66.3 (56.7 to 74.8) | 58.3 (48.3 to 67.7) | 8.0 (− 5.5 to 21.1) |
Total no. of failures | 34 (33.7) | 40 (41.7) | |
No. with missing data | 15 (14.9) | 19 (19.8) | |
No. with early treatment failure | 0 | 0 | |
No. with late clinical failure | 5 (5.0) | 2 (2.1) | |
No. with late parasitological failure | 14 (13.9) | 19 (19.8) | |